Navigation Links
European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease
Date:3/31/2011

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Wilson disease is a rare genetic storage disorder in which copper is not excreted by the body effectively, leading to excess copper build up, liver failure and damage to the brain (neurological problems). Worldwide the condition, affects approximately one in 30,000 people. If not treated, Wilson disease can be chronically debilitating and life threatening. While current guidelines recommend the use of chelating agents (D-penicillamine, trientine) as first line therapy of symptomatic patients, optimal treatment regimens are yet to be established.

In this retrospective multicentre cohort study the long-term outcomes of treatment with D-penicillamine and trientine were reviewed in 347 patients with the condition. Changes of medication were common in both groups and resulted in a total of 467 analysed treatments (D-penicillamine, n=326, trientine n=141). Following an average follow-up of 16.5 years, both treatments provided a similar and excellent survival rate and prevented disease progression with the need for liver transplantation in over 98% of patients.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman commented: "Not only does this study show that both treatments are effective options for patients with this rare and often debilitating condition, but it is also encouraging to see how European countries can work together and exchange data which is extremely valuable to guide best practice and evaluate existing treatment regimens. Research on rare liver diseases presents remarkable interest."

"To date, a very limited number of drugs for these conditions are marketed, leaving the majority of rare diseases without any effective treatment. Research into rare diseases and possible cures needs to be strongly encouraged."

Follow-up at 48 months showed that liver deterioration occurred in only 8 out of 515 treatments (D-penicillamine n=4, trientine n=4) while neurological deterioration was less frequent in the D-penicillamine group (7/326 treatments) compared to trientine (12/141, p≤=0.05). Improvements in liver function of symptomatic patients was similar between groups when data were stratified between first and second line treatments, with improvement rates during first line therapy in symptomatic patients of 90.7% for D-penicillamine and 92.6% for trientine.


'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-790-013-8904
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. UC Riverside researcher receives $9 million USDA grant to study potato and tomato disease
2. New study shows you can have your candy and eat it too -- without adverse health effects
3. Study: Emissions trading doesnt cause pollution hot spots
4. Butterfly study reveals traits and genes associated with establishment of new populations
5. Study shows hunger hitting closer to home
6. Most states unclear about storage, use of babies blood samples, new study finds
7. GPS study shows wolves more reliant on a cattle diet
8. Russian boreal forests undergoing vegetation change, study shows
9. Spicing up your love life possible, study finds
10. Study finds weight training safe for pregnant women
11. Study predicts large regional changes in farmland area
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... ... has announced the move of the SPIE Digital Library ( http://www.spiedigitallibrary.org ) on ... SPIE to create an improved user experience and incorporate a number of enhancements ...
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... , ... September 14, 2017 , ... ... minds in pharma and biotech at the third annual DrugDev Summit, November 7-8, ... brings together the world’s most progressive clinical research leaders for best practice case ...
(Date:9/14/2017)... , ... September 14, 2017 , ... ... Freedom Lumbar Disc case in Australia. Dr. Steven Yang completed the procedure on ... a result of a degenerative lumbar disc at level L5-S1. The patient failed ...
Breaking Biology Technology: